8-K/A: Vivos Therapeutics Corrects Filing, Dilutes Shares

Vivos Therapeutics, Inc. amends a prior filing to correct the report date and disclose the issuance of over 11 million shares to Streeterville Capital, LLC, significantly diluting existing shareholders.

Summary

• Vivos Therapeutics, Inc. (the Company) has filed an amendment to a previous Form 8-K report to correct the original report date from September 4, 2026, to September 2, 2026.
• The amendment clarifies that transactions disclosed in the original report were consummated on September 2, 2026.
• The Company entered into twelve exchange agreements with Streeterville Capital, LLC to partition an aggregate of $2,861,270.00 of the outstanding principal balance of a secured promissory note.
• In exchange for surrendering these partitioned notes, Vivos Therapeutics issued an aggregate of 11,445,080 shares of its Common Stock to Streeterville Capital, LLC.
• These shares represent approximately 52% of the Company's issued and outstanding Common Stock immediately prior to the exchanges and approximately 34% immediately following the exchanges.
• The issuance of these shares was made in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.
• Following these exchanges, the outstanding principal balance of the Streeterville Note was reduced to $3.7 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to significant equity dilution and the correction of a previously filed report, indicating potential disclosure issues.

Positives

• The outstanding principal balance of the Streeterville Note has been reduced by $2,861,270.
• The company corrected a previous filing to accurately reflect transaction dates.

Negatives

• Significant equity dilution occurred with the issuance of 11,445,080 shares, representing approximately 34% of the outstanding common stock post-issuance.
• The filing is an amendment to a previous report, indicating an initial error in reporting the effective date of transactions.
• The issuance of shares to Streeterville Capital, LLC, in exchange for debt, significantly increases the number of outstanding shares.

Risks

• Potential for further dilution if the remaining $3.7 million principal of the Streeterville Note is converted into equity.
• The large issuance of shares could negatively impact the market price of the Common Stock.
• The need to amend a prior filing suggests potential issues with internal controls or disclosure processes.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the details of the debt-for-equity exchange and the remaining debt balance.

Management Comments

• The Company is filing this Amendment to its Current Report on Form 8-K dated September 4, 2026, to correct the date of the Original 8-K.
• The transactions disclosed under Items 1.01 and 3.02 were consummated on September 2, 2026.
• This Amendment is being filed solely to reflect September 2, 2026 as the Date of Report and to amend Items 1.01 and 3.02 thereof to reflect the fact that the transactions reported in the Original 8-K were consummated on September 2, 2026.

Industry Context

StockSavvy.ai notes that debt-for-equity exchanges are a common, albeit often dilutive, method for companies, particularly those in early stages or facing financial pressures, to manage outstanding debt. The significant dilution here suggests Vivos Therapeutics is prioritizing debt reduction over maintaining existing shareholder equity value in the short term.

Stakeholder Impact

• Shareholders: Face significant dilution of their ownership stake and potential decrease in stock value due to the large issuance of new shares.
• Creditors: The principal debt to Streeterville Capital, LLC has been reduced, improving the company's debt-to-equity ratio from the perspective of remaining creditors.
• Streeterville Capital, LLC: Becomes a significantly larger shareholder in Vivos Therapeutics, Inc.

Next Steps

• Streeterville Capital, LLC will surrender each Partitioned Note for cancellation on the date the related Exchange Shares become free trading.
• The Company will continue to manage the remaining $3.7 million principal balance of the Streeterville Note.

Key Dates

Recommendation

The significant equity dilution resulting from the debt-for-equity exchange, coupled with the correction of a prior filing, presents a negative outlook. The issuance of shares representing approximately 34% of the company's outstanding stock will likely depress the share price and reduce the value of existing holdings. Investors should consider selling to avoid further dilution.

Keywords

Vivos Therapeutics, Form 8-K/A, Streeterville Capital, Promissory Note, Equity Issuance, Share Dilution, Securities Act, Common Stock